Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.70 |
| ▸ | RAB9A | P51151 | 11/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.70 |
| ▸ | GLA | P06280 | 1/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.54 |
| ▸ | RELA | Q04206 | 1/20 | 0.54 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31110119 | 1.00 | NPC1 (0.70) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL25143648 | 0.89 | NPC1 (0.63) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL4865759 | 0.85 | RAB9A (0.58) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL25143173 | 0.85 | NPC1 (0.74) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL31665320 | 0.85 | NPC1 (0.74) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL24074609 | 0.85 | PTGS1 (0.54) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL8357652 | 0.83 | NPC1 (0.56) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL25142548 | 0.82 | NPC1 (0.55) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL890943 | 0.82 | RAB9A (0.70) | NPC1RAB9AKDM4ETP53SMN1; SMN2 | |
| SCHEMBL31110226 | 0.82 | NPC1 (0.55) | NPC1RAB9AKDM4ETP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7129245-B2 | Anticoagulants which act selectively on factor Xa; fast acting; oral; do not interfere with lysis of blood clots | ELI LILLY AND COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| US-20050282862-A1 | Aromatic amides | BEIGHT DOUGLAS W | 2005-12-22 | — | — | US | disclosed |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1456175-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040058959-A1 | Substituted carboxamides | HERRON DAVID KENT (US) | 2004-03-25 | — | — | US | disclosed |
| US-20040029874-A1 | Aromatic amides | BEIGHT DOUGLAS WADE (US) | 2004-02-12 | — | — | US | disclosed |
| EP-1379506-A2 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6635657-B1 | Pyridine derivatives; anticoagulants | ELI LILLY AND COMPANY | 2003-10-21 | — | — | US | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-1307444-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002064567-A2 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
| WO-2002010154-A2 | SUBSTITUTED HETEROCYCLIC AMIDES | ELI LILLY AND COMPANY (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-1140903-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039118-A1 | AROMATIC AMIDES | ELI LILLY AND COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029874-A1 | Aromatic amides | F11, F12, F5 | NPC1 1659/4885RAB9A 2097/4885KDM4E 1065/4885 |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | F11, SERPINC1, TFPI | NPC1 2571/4885RAB9A 3682/4885KDM4E 2131/4885 |
| US-20050282862-A1 | Aromatic amides | F11, F12, F5 | NPC1 1659/4885RAB9A 2097/4885KDM4E 1065/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | NPC1 3357/4885RAB9A 3234/4885KDM4E 1896/4885 |
| US-20040058959-A1 | Substituted carboxamides | F11, F12, TFPI | NPC1 2362/4885RAB9A 3125/4885KDM4E 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.